Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

As more Chinese factories turn to tech for cost-cutting and quality controls, it’s going to be even harder to resist buying ...

AstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

Survival rates among breast cancer patients whose cancer is detected before it spreads are high, between 86% and 89%. Yet if ...

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.

Breast cancer patients whose tumors have spread to other parts of their bodies live from scan to scan. Is their treatment ...